Search results
CHWY Stock Up 13% Following Solid Q4 Performance Despite Earnings Miss
Chewy, Inc. CHWY reported solid fourth-quarter fiscal 2025 results, wherein the top line beat the Zacks Consensus Estimate and the bottom line missed the same. Also, sales increased and earnings
Norwegian Cruise Line Holdings Ltd. (NCLH) is Attracting Investor Attention: Here is What You Should Know
Norwegian Cruise Line (NCLH) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of
Why Norwegian Cruise Line (NCLH) Dipped More Than Broader Market Today
Norwegian Cruise Line (NCLH) closed at $19.85 in the latest trading session, marking a -1.83% move from the prior day. This move lagged the S&P 500's daily loss of 1.74%. Meanwhile, the Dow lost
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.52 per share a year ago. These figures
Acco Brands (ACCO) Matches Q4 Earnings Estimates
Acco Brands (ACCO) came out with quarterly earnings of $0.38 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.39 per share a year ago. These figures are
AIZ Stock Trading at a Discount to Industry at 1.9X: Time to Hold?
Assurant, Inc. AIZ shares are trading at a discount compared with the Zacks Multi-line Insurance industry. Its forward price-to-book value of 1.9X is lower than the industry average of 2.25X, the Fi
Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026?
Merck MRK continues to face challenges with its second-largest product, Gardasil, which is a vaccine approved to prevent certain cancers caused by the human papillomavirus. While the vaccine’s sales
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study
Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients with estrogen receptor (ER)-positive, human
Canadian Natural Q4 Earnings Beat Estimates, Expenses Decrease Y/Y
Canadian Natural Resources Limited CNQ reported fourth-quarter 2025 adjusted earnings per share of 59 cents, which beat the Zacks Consensus Estimate of 53 cents. However, the bottom line decreased
Should Investors Buy Old Dominion Stock Post Dividend Hike?
Last month, Old Dominion Freight Line, Inc. (ODFL) stated that its board of directors had announced an increase in its quarterly dividend payout, reflectingthe company’s commitment to boosting
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.09 per share a year ago. These figures are adjusted
Custom Truck One Source, Inc. (CTOS) Matches Q4 Earnings Estimates
Custom Truck One Source, Inc. (CTOS) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.04 per share a year ago. These
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago. These figures are adjusted for
Petrobras Q4 Earnings Beat as Output Growth Offsets Oil Drop
Petroleo Brasileiro S.A., or Petrobras PBR, posted fourth-quarter earnings per ADS of 72 cents, beating the Zacks Consensus Estimate of 57 cents. The bottom line improved from the year-ago profit of
AEG or PUK: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Insurance - Multi line sector have probably already heard of Aegon NV (AEG) and Prudential (PUK). But which of these two stocks presents investors with the
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma
GSK plc GSK signed a license agreement with Italy-based Alfasigma. Per the terms of the agreement, Alfasigma has acquired exclusive global rights from GSK to develop and market linerixibat, an
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Shares of Xenon Pharmaceuticals XENE surged 49.6% yesterday after the company announced positive top-line data from the phase III X-TOLE2 study, which evaluated its lead pipeline candidate
Recurring Contracts & Solid Liquidity Aid Booz Allen Amid Rising Costs
Booz Allen Hamilton’s BAH top line is gaining from long-term government contracts, providing steady revenues and offsetting market volatility. The company’s strong strategies improve operational
Vail Resorts Q2 Earnings and Revenues Miss Estimates, Guidance Lowered
Vail Resorts, Inc. MTN reported dismal second-quarter fiscal 2026 results, with earnings and revenues missing the Zacks Consensus Estimate. On a year-over-year basis, both the top and bottom lines
Groupon (GRPN) Q4 Earnings Meet Estimates
Groupon (GRPN) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $1.2 per share a year ago. These figures are adjusted for


